Bispecific antibody · Immune activation, directed at B-cell maturation antigen (TNFRSF17) and CD3 (CD3E) · developed by Cullinan Therapeutics
Velinotamig is an engineered bispecific antibody that binds BCMA and CD3. It is being studied in immune thrombocytopenia and warm autoimmune hemolytic anemia.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07738822 | Phase 1/2 | Immune Thrombocytopenia (ITP) | Not yet recruiting | CGEM |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Immune Thrombocytopenia (ITP)Warm Autoimmune Hemolytic Anemia (WAIHA)
Updated Nov 8, 2026. Something wrong or missing? Report it on the CGEM page.
See CGEM's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
CGEM catalysts and pipeline →